Caresyntax raises $180M to support AI-powered surgical software

Caresyntax today announced it has raised $180 million in an extended Series C funding round and an expansion round of growth debt.

Symbiotic Capital, MTIP AG, BIONIQ Capital, PFM Health Sciences, Pictet Alternative Advisors, surgical.ai, BlackRock Innovation Capital, Aescuvest, Optum Ventures, Cure Capital, Relyens Group, Vesalius Biocapital, Lauxera Capital, Plug & Play Growth Fund and ProAssurance Corp. all contributed to the round. Caresyntax raised $80 million in equity and up to $100 million in growth debt.

San Francisco-based vendor-neutral precision surgery platform developer aims to transform surgery with a scalable, comprehensive software platform and AI. Caresyntax’s interoperable medical platform enables the capture and use of new data and applications. Helps improve surgical precision and patient safety.

The platform also addresses critical data gaps and fragmentation challenges that can hinder the advancement of precision, data-driven surgery, according to a press release.

Caresyntax leverages technology and AI to collect, integrate, and analyze unique and comprehensive data. The platform provides real-time, long-term clinical decision support that streamlines the patient journey. The technology also increases hospital operational efficiency and leads to improved patient outcomes and profitability.

Together with our partners and investors, we are working to bring precision surgical tools, powered by data and AI, to improve patient outcomes,” said Dennis Kogan, co-founder and CEO of Caresyntax. “This funding is not just an investment in Caresyntax, but an investment in the future of surgery. I am grateful to our investors who are driving and believe in the power of intelligent data and AI in the operating room.”